Embryonic stem cells, clinical applications and methods for expanding in vitro

• US 20030064059A1
• Filed: 10/25/2002
• Published: 04/03/2003
• Est. Priority Date: 07/18/2001
• Status: Abandoned Application

• Current Assignee: Medra, Inc.
• Original Assignee: Medra, Inc.
• Inventors: Rader, William C., Scheller, Albert
• Application Number:
  US10/280,791
• Publication Number:
  US 20030064059A1
• Time in Patent Office: Days
• US Class Current: 424/93.21
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C12N 2501/115 Basic fibroblast growth factor (bFGF, FGF-2)
• CPC Class Codes: C12N 2501/235 Leukemia inhibitory factor [LIF]
• CPC Class Codes: C12N 2503/00 Use of cells in diagnostics
• CPC Class Codes: C12N 5/0606 Pluripotent embryonic cells, e.g. embryonic stem cells [ES] embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696

Abstract

The present invention provides a method for the in vitro culture of embryonic stem cells, wherein the stem cells continue to express no antigen or antigen CD117, and mostly remain undifferentiated during culture. The present invention also relates to purified preparations of embryonic stem cells and for uses of embryonic stem cells in treating a wide variety of conditions, diseases and disorders.

Claims

1. A method for treating patients with a condition, disease or disorder selected from the group consisting of sickle cell disease, Downs syndrome, leukemia, systemic lupus erythematosus rheumatoid arthritis, osteoporosis, multiple sclerosis, amyotrophic lateral sclerosis, cerebral palsy, brain damage, Parkinson'"'"'s disease, early stage Alzheimer'"'"'s disease, stroke, hypoxic disorders, autism, type I diabetes, cancer, depression, hemophilia, heart disease, muscoviscidosis, and mycoacidosis, comprising the steps of:

administering hematopoietic stem cells to the patient via intravenous injection; and

administering neuronal stem cells to the patient via subcutaneous injection.

2. The method of claim 1, wherein about 10 million to about 100 million hematopoietic stem cells and about 10 million and to about 80 million neuronal stem cells are administered to the patient.

3. The method of claim 1, wherein the hematopoietic stem cells and the neuronal stem cells are prepared by introducing embryonic stem cells into a chemically defined culture medium containing a growth factor, applying a microcurrent to the culture medium containing the stem cells, and incubating the culture medium containing the stem cells at a temperature from about 34°

C. to about 42°

C.

4. The method of claim 1, wherein the hematopoietic stem cells and the neuronal stem cells are extracted from a human embryo.

5. The method of claim 1, further comprising the step of performing aplasia of the patient'"'"'s bone marrow prior to administering the hematopoietic stem cells and the neuronal stem cells.